



NDA 022350/S-001 & S-002

**SUPPLEMENT APPROVAL**

Bristol-Myers Squibb Company  
Attention: Pamela J. Smith, M.D.  
Group Director, GRS  
P.O. Box 4000  
Princeton, NJ 08543-4000

Dear Dr. Smith:

Please refer to your supplemental New Drug Applications (NDAs) dated and received April 19, 2010, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Onglyza (saxagliptin) tablets, 2.5 mg and 5 mg.

We acknowledge receipt of your amendments dated July 21, August 10, 20, and 24 (2), September 16, December 6 and 29, 2010, and January 25, and February 9, 2011.

S-001: This “Prior Approval” supplemental new drug application provides for the following changes:

1. Amends the package insert with results from Study D1680C00001/CV181054 entitled, *“Double-blind, Active-controlled, Phase III Study with a 52-Week Extension Period to Evaluate the Safety and Efficacy of Saxagliptin in Combination with Metformin Compared with Sulphonylurea in Combination with Metformin in Adult Patients with Type 2 Diabetes who have Inadequate Glycemic Control on Metformin Therapy Alone.”*
2. Adds a description to the Pharmacokinetics section of the package insert with results from Study CV181067 entitled, *“Effect of Saxagliptin on the Pharmacokinetics of the Active Moieties of a Combined Oral Contraceptive (COC) Containing Ethinyl Estradiol and Norgestimate in Healthy Female Subjects.”*
3. Amends the Pregnancy section of the package insert based on the results of two nonclinical embryofetal studies entitled, *“Saxagliptin ... and Metformin ... : Oral Combination Study of Embryo-fetal Development in Rats (II)”* and *“Saxagliptin ... and Metformin ... Oral Combination Study of Embryo-fetal Development in Rabbits.”*

S-002: This “Prior Approval” supplemental new drug application amends the package insert with results from Study D1680C00007/CV181062 entitled, *“A Short-term 12-Week, Multi-centre, Randomized, Parallel-group, Double-blind, Placebo-controlled Study to Evaluate the Treatment Effect of Saxagliptin compared with Placebo in Adult Patients with Type 2 Diabetes and Renal*

*Impairment (Moderate, Severe, and End-Stage) with an Additional 40-week, Randomized, Parallel-group, Double-blind, Placebo-controlled Long-term Observational Period (Short-term Clinical Study Report).”*

We have completed our review of these supplemental applications, as amended. They are approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

### **CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling text for the package insert, with the addition of any labeling changes in pending “Changes Being Effectuated” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eLIST may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As” at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

### **REQUIRED PEDIATRIC ASSESSMENTS**

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because none of these criteria apply to your application, you are exempt from this requirement.

### **PROMOTIONAL MATERIALS**

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit the following, in triplicate, (1) a cover letter requesting advisory comments, (2) the proposed materials in draft or mock-up form with annotated references, and (3) the package insert(s) to:

Food and Drug Administration  
Center for Drug Evaluation and Research  
Division of Drug Marketing, Advertising, and Communications  
5901-B Ammendale Road  
Beltsville, MD 20705-1266

You must submit final promotional materials and package insert(s), accompanied by a Form FDA 2253, at the time of initial dissemination or publication [21 CFR 314.81(b)(3)(i)]. Form FDA 2253 is available at <http://www.fda.gov/opacom/morechoices/fdaforms/cder.html>; instructions are provided on page 2 of the form. For more information about submission of promotional materials to the Division of Drug Marketing, Advertising, and Communications (DDMAC), see <http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm>.

### **LETTERS TO HEALTH CARE PROFESSIONALS**

If you decide to issue a letter communicating important safety-related information about this drug product (i.e., a “Dear Health Care Professional” letter), we request that you submit, at least 24 hours prior to issuing the letter, an electronic copy of the letter to this NDA to the following address:

MedWatch Program  
Office of Special Health Issues  
Food and Drug Administration  
10903 New Hampshire Ave  
Building 32, Mail Stop 5353  
Silver Spring, MD 20993

### **REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Rachel Hartford, Regulatory Project Manager, at (301) 796-0331.

Sincerely,

*{See appended electronic signature page}*

Mary H. Parks, M.D.  
Director  
Office of Drug Evaluation II  
Center for Drug Evaluation and Research

ENCLOSURE:  
Package Insert

-----  
**This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.**  
-----

/s/  
-----

MARY H PARKS  
02/18/2011